WITHDRAWN: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis (Q36884914)

16 August 2017

1 reference

retracted paper

0 references

title

WITHDRAWN: Gonadotrophin-releasing hormone analogues for pain associated with endometriosis (English)

1 reference

16 August 2017

1 reference

A Prentice

1

1 reference

16 August 2017

A J Deary

2

1 reference

16 August 2017

S Goldbeck-Wood

3

1 reference

16 August 2017

C Farquhar

4

1 reference

16 August 2017

S K Smith

5

1 reference

16 August 2017

1 January 1999

1 reference

Cochrane Database of Systematic Reviews

16 August 2017

1 reference

16 August 2017

2

1 reference

16 August 2017

CD000346

1 reference

Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol

16 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000346.PUB2

Crossref

reference URL

Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Efficacy and safety of nafarelin in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Short-term Lupron or danazol therapy for pelvic endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Nafarelin in the treatment of pelvic pain caused by endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin-releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Buserelin versus danazol in the treatment of endometriosis-associated infertility

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A comparison of nafarelin acetate and danazol in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Changes in bone mineral content following hormone treatment for endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Endocrine effects of GnRH analogue with low-dose hormone replacement therapy in women with endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Vaginal patterns during danazol and buserelin acetate therapy for endometriosis: structural and ultrastructural study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Nafarelin therapy in endometriosis: long-term effects on bone mineral density

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Postsurgical medical treatment of advanced endometriosis: Results of a randomized clinical trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Nafarelin versus danazol in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Goserelin depot versus danazol in the treatment of endometriosis the Australian/New Zealand experience

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Effects of nafarelin versus danazol on lipids and calcium metabolism

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl)

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Endometriosis and pelvic pain

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD000346.PUB2

Identifiers

DOI

10.1002/14651858.CD000346.PUB2

1 reference

16 August 2017

1 reference